0001264124-12-000183.txt : 20120810
0001264124-12-000183.hdr.sgml : 20120810
20120810183501
ACCESSION NUMBER: 0001264124-12-000183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120808
FILED AS OF DATE: 20120810
DATE AS OF CHANGE: 20120810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Costa Paulo F
CENTRAL INDEX KEY: 0001465928
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19700
FILM NUMBER: 121025595
MAIL ADDRESS:
STREET 1: 9360 TOWNE CENTRE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000881464
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330266089
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9360 TOWNE CENTRE DR
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 6195522200
MAIL ADDRESS:
STREET 1: 9360 TOWNE CENTRE DR
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2012-08-08
1
0000881464
AMYLIN PHARMACEUTICALS INC
AMLN
0001465928
Costa Paulo F
9360 TOWNE CENTRE DR
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2012-08-08
4
J
0
24933.0
31.0
D
1067.0
D
Common Stock
2012-08-08
4
J
0
1067.0
31.0
D
0.0
D
Non-Qualified Stock Option (right to buy)
11.26
2012-08-08
4
J
0
30000.0
31.0
D
2016-06-09
Common Stock
30000.0
0.0
D
Non-Qualified Stock Option (right to buy)
13.18
2012-08-08
4
J
0
20000.0
31.0
D
2018-05-24
Common Stock
20000.0
0.0
D
Non-Qualified Stock Option (right to buy)
21.52
2012-08-08
4
J
0
20000.0
31.0
D
2017-04-29
Common Stock
20000.0
0.0
D
Non-Qualified Stock Option (right to buy)
27.3
2012-08-08
4
J
0
20000.0
31.0
D
2019-05-15
Common Stock
20000.0
0.0
D
Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes 3,000 unvested restricted stock units that were cancelled at the effective time of the merger pursuant to the merger agreement in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were fully vested immediately prior to and cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
By: /s/ James R Oehler, Attorney-in-Fact For: Paulo F Costa
2012-08-10